Practice Areas - Equity Capital Markets Law Firms and Lawyers
| Deal Date: | 09-07-2020 | Practice Area: | Equity Capital Markets |
| Deal Title: | Ocumension Therapeutics HKSE Initial Public Offering | Industry: | Pharmaceuticals & Biotechnology |
| Description: |
Davis Polk advised the underwriters in the initial public offering of Ocumension Therapeutics on the Hong Kong Stock Exchange and an international offering and listing in reliance on Rule 144A and Regulation S. The gross proceeds from the offering amounted to approximately HKD1.55 billion (USD200.4 million) prior to any exercise of the over-allotment option.
Ocumension is a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing and commercializing first- or best-in-class ophthalmic therapies and has, in less than three years, built a strategically designed ophthalmic drug portfolio that is comprehensive, innovative and validated.
|
||
| Financial Center: | Hong Kong | Value: | 100.01-500.00 |
| Advised Party: | Underwriter | Law Firm | Davis Polk |
| Issuer Jurisdiction- | China | Listing Jurisdiction- | Hong Kong |
| Classification: |
Initial Public Offerings Hong Kong Stock Exchange |
Lawyer | Li He |
